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Abstract
2p16.3 deletions, involving heterozygous NEUREXIN1 (NRXN1) deletion, dramatically increase the risk of developing
neurodevelopmental disorders, including autism and schizophrenia. We have little understanding of how NRXN1
heterozygosity increases the risk of developing these disorders, particularly in terms of the impact on brain and
neurotransmitter system function and brain network connectivity. Thus, here we characterize cerebral metabolism and
functional brain network connectivity in Nrxn1α heterozygous mice (Nrxn1α+/− mice), and assess the impact of ketamine
and dextro-amphetamine on cerebral metabolism in these animals. We show that heterozygous Nrxn1α deletion alters
cerebral metabolism in neural systems implicated in autism and schizophrenia including the thalamus, mesolimbic
system, and select cortical regions. Nrxn1α heterozygosity also reduces the efficiency of functional brain networks, through
lost thalamic “rich club” and prefrontal cortex (PFC) hub connectivity and through reduced thalamic-PFC and thalamic “rich
club” regional interconnectivity. Subanesthetic ketamine administration normalizes the thalamic hypermetabolism and
partially normalizes thalamic disconnectivity present in Nrxn1α+/− mice, while cerebral metabolic responses to
dextro-amphetamine are unaltered. The data provide new insight into the systems-level impact of heterozygous Nrxn1α
deletion and how this increases the risk of developing neurodevelopmental disorders. The data also suggest that the
thalamic dysfunction induced by heterozygous Nrxn1α deletion may be NMDA receptor-dependent.
Key words: autism, functional brain imaging, graph theory, NMDA receptor, schizophrenia
Introduction
Copy number variants (CNVs) are strongly implicated in the
genetic etiology of schizophrenia (ScZ) and autism (ASD).
Population-based studies show that deletions at 2p16.3, involv-
ing heterozygous deletion of the NEUREXIN1 (NRXN1) gene,
are associated with developmental delay, learning difficulties,
and a dramatically increased risk of developing ASD (odds
ratio=14.9) (Matsunami et al. 2013; Yuen et al. 2017) and
ScZ (odds ratio=14.4) (Marshall et al. 2017). Individuals with
NRXN1 deletions also show symptoms of attention deficit
hyperactivity disorder (ADHD) (Ching et al. 2010; Schaaf et al.
2012). Heterozygous NRXN1α deletions were first reported in
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small case studies of individuals with ASD (Friedman et al. 2006)
and ScZ (Kirov et al. 2009) and have subsequently been identified
in other cases (see Reichelt et al. 2012 for review). Most NRXN1
deletions observed in ScZ and ASD localize to the promoter and
initial exons ofNRXN1α and leave theNRXN1β coding sequences
intact (Reichelt et al. 2012); thus, they are predicted to impact on
NRXN1α but not NRXN1β transcripts.
Neurexins function as presynaptic cell adhesion molecules
forming trans-synaptic interaction complexes with a range of
postsynaptic binding partners, including neuroligins, to regu-
late synaptic differentiation, maturation, and function (Reichelt
et al. 2012; Sudhof 2008, 2017). Neurexins undergo extensive
alternative splicing, which regulates their binding interactions,
with isoforms being differentially expressed throughout the
brain and across development (Ullrich et al. 1995; Schreiner et
al. 2014; Treutlein et al. 2014).
Multiple rodent studies have been dedicated to elucidating
the behavioral consequences of neurexin deficiency to establish
whether these result in phenotypes relevant to ASD and ScZ.
For example, Nrxn1α homozygous knockout (KO) mice display
decreased social interaction and increased anxiety-like behavior
(Grayton et al. 2013),whichmay relate to core symptoms of these
disorders, along with a deficit in prepulse inhibition (Etherton
et al. 2009) that mirrors the sensorimotor gating deficits seen
in ASD and ScZ (Braff et al. 1999; Cheng et al. 2018). Studies
undertaken in Nrxn1α KO rats also support a role for Nrxn1α
in cognition and learning, but found no evidence for altered
sensorimotor gating (Esclassan et al. 2015). As NRXN1 deletions
in ASD and ScZ are commonly heterozygous, other studies have
focused on Nrxn1α heterozygous (Nrxn1α+/−) mice, reporting
sex-dependent alterations in novelty responsiveness and habit-
uation (Laarakker et al. 2012) and memory deficits (Dachtler et
al. 2015). Nrxn1α+/− mice also show deficits in social memory,
while effects on sociability and anxiety-like behavior appear to
be limited (Grayton et al. 2013; Dachtler et al. 2015).
Evidence implicates glutamate neurotransmitter system and
NMDA receptor (NMDA-R) dysfunction in ASD (Lee et al. 2015;
Horder et al. 2018) and ScZ (Howes et al. 2015; Dauvermann et
al. 2017), and the NMDA-R is proposed as a potential therapeu-
tic target in both disorders. Drugs modulating NMDA-R func-
tion are hypothesized as potential treatments for ScZ (Dauver-
mann et al. 2017),while evidence suggests that either facilitating
or reducing NMDA-R function may have therapeutic potential
in ASD (Lee et al. 2015). For example, the NMDA-R antago-
nist, Memantine, shows clinical promise for some ASD symp-
toms (Chez et al. 2007; Ghaleiha et al. 2013), although positive
effects are not always found (Aman et al. 2017). The reason for
the disparity between studies is unknown but may relate to
disease heterogeneity. Thus, predictive biomarkers of NMDA-R
drug efficacy, to allow patient stratification and a personalized
medicine approach, in ASD are urgently needed. There is also
strong evidence to support monoamine (dopamine, serotonin,
and noradrenaline) system dysfunction in ScZ and ASD (Selvaraj
et al. 2014; Howes et al. 2015; Muller et al. 2016). For example,
responses to the monoaminergic releasing stimulant dextro-
amphetamine (d-amphetamine) are altered in ScZ (Breier et al.
1997; Swerdlow et al. 2018), while the drug is used therapeuti-
cally in ASD (Nickels et al. 2008; Cortese et al. 2012).
Our understanding of the impact ofNrxn1α heterozygosity on
glutamate and monoamine neurotransmitter system function
is incomplete. However, Nrxn1α has been shown to regulate
glutamatergic synapse formation (Siddiqui et al. 2010), and com-
plete ablation of Nrxn1α impairs excitatory, but not inhibitory,
neurotransmission in the hippocampus (Etherton et al. 2009).
Moreover, Nrxn1α’s interactions with leucine-rich repeat
transmembrane proteins (LRRTMs) may act to regulate exci-
tatory synapse formation, postsynaptic glutamate receptor
levels (including the NMDA-R and AMPA-R), glutamatergic
neurotransmission, and NMDA-R-dependent LTP (de Wit et al.
2009; Soler-Llavina et al. 2011; Siddiqui 2013, Um 2016). Nrxn1α
may also influence glutamatergic neurotransmission through
its interactions with cerebellins (C1qls), which bind with high
affinity to postsynaptic kainite (GluK2, GluK4) and AMPA-R
(GluA1) glutamate receptors (Cheng et al. 2016; Matsuda et
al. 2016). Similarly, through its interactions with neuroligin 1
(Nrlgn1), Nrxn1α can also modulate glutamatergic synaptic
function through the modification of NMDA-R and AMPA-R
function (Chubykin et al. 2007; Barrow et al. 2009; Espinosa et al.
2015; Chanda et al. 2017). More recently, alternative splicing of
presynaptic Nrxn1, at splice site 4 (SS4), has also been shown to
regulate postsynaptic NMDA-R function (Dai et al. 2019), further
linking Nrxn1 to the regulation of the NMDA-R. In addition,
Nrxn1 regulates presynaptic neurotransmitter release, in part
through the regulation of Ca2+ channels, presynaptic Ca2+
transients, and subsequent synaptic vesicle exocytosis (Missler
et al. 2003; Pak et al. 2015; Chen et al. 2017; Tong et al. 2017;
Brockhaus et al. 2018). Despite these observations, the impact
of Nrxn1α heterozygosity on in vivo glutamate/NMDA-R and
monoaminergic system function has not been characterized.
Between the relatively well-characterized molecular and
behavioral effects of Nrxn1α, we have little understanding of the
systems-level alterations that result fromNrxn1aheterozygosity.
This includes the impact on brain function, brain network
connectivity, and neurotransmitter system function. Here, we
characterize the impact of Nrxn1α heterozygosity on cerebral
metabolism and functional brain network connectivity. In
addition, we characterize the cerebral metabolic response to
ketamine and d-amphetamine to elucidate the impact ofNrxn1a
heterozygosity on in vivo NMDA-R and monoaminergic system
function.
Materials and Methods
Animals
Full animal details can be found in the study of Dachtler et al.
(2014). In brief,male B6;129-Nrxn3tm1Sud/Nrxn1tm1Sud/Nrxn2tm1Sud/J
mice (The Jackson Laboratory, Stock #006377) were purchased
as heterozygous KO at Nrxn1α, homozygous KO at Nrxn2, and
wild-type (WT) at Nrxn3 and outbred to the C57BL/6NCrl strain
(Charles River, Margate, UK) to obtain mice individually het-
erozygous for Nrxn1α. Experimental animals (Nrxn1a+/− andWT
littermates, aged 10–22 weeks) were generated through cousin
mating. Animals were group housed (4–6/cage) under standard
conditions (individually ventilated cages, 21◦C,45–65%humidity,
12 h:12 h dark/light cycle, lights on at 06:00) with food and
water access ad libitum. Experiments were carried out in com-
pliancewith theUKAnimals (Scientific Procedures) Act 1986 and
approved by the Lancaster University AnimalWelfare and Ethics
Review Board.
14C-2-Deoxyglucose Functional Brain Imaging
14C-2-deoxyglucose (14C-2-DG) functional brain imaging was
conducted in accordance with published protocols (Daw-
son et al. 2015). In brief, local cerebral glucose utilization
(LCGU) measurement was initiated by injection of 14C-2-DG
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(“intraperitoneally” [i.p.]), 4.625 MBq/kg in physiological saline at
2.5 mL/kg (American Radiolabelled Chemicals Inc.) 1 min after
25mg/kg (R,S)-ketamine (Sigma-Aldrich) or 15min after 5mg/kg
d-amphetamine (Sigma-Aldrich) administration (i.p. at 2 mL/kg
in saline). Vehicle controls received saline vehicle administra-
tion (2 mL/kg i.p.) 1 or 15 min before 14C-2-DG injection (50%
sample at each time). About 45min after 14C-2-DG injection, ani-
mals were decapitated and a terminal blood sample collected,
by torso inversion, into heparinized weigh boats. Plasma glucose
concentrations (mmol/L) were detected from whole blood
(Accu-Chek Aviva). The brain was then rapidly dissected out
intact, frozen in isopentane (−40◦C), and stored at (−80◦C) until
sectioning. Blood samples were centrifuged to isolate plasma,
and plasma (20 μL) 14C concentrationswere determined by liquid
scintillation analysis (Packard). Frozen brains were sectioned
(20 μm) in the coronal plane in a cryostat (−20◦C). A series of
three consecutive sections were retained from every 60 μm,
thawmounted onto slide covers, and rapidly dried on a hotplate
(70◦C). Autoradiograms were generated by apposing these
sections, together with precalibrated 14C standards (39–1098
nCi/g tissue equivalents, American Radiolabelled Chemicals
Inc) to X-ray film (Carestream BioMax MR film, Sigma-Aldrich,
UK) for 7 days. Autoradiographic images were analyzed by a
computer-based image analysis system (MCID/M5+, Interfocus).
The local isotope concentration for each brain region of
interest (RoI) was derived from the optical density of the
autoradiographic images relative to that of the coexposed 14C
standards. LCGU was determined in 59 brain regions of interest
(RoI) across a range of neural systems (Supplementary Material,
Supplementary Table 1) with reference to a stereotaxic mouse
brain atlas (Paxinos and Franklin 2001). The rate of LCGU, in each
RoI, was determined as the ratio of 14C present in that region
relative to that of the whole brain 14C concentration in the same
animal, referred to as the 14C-2-DG uptake ratio. Group sizes
were WT: saline-treated n=8 (male n=5), ketamine-treated
n=9 (male n=4), d-amphetamine-treated n=9 (male n=4);
Nrxn1a+/−: saline-treated n=10 (male n=5), ketamine-treated
n=13 (male n=6), d-amphetamine-treated n=11 (male n=6).
Statistical Analysis
LCGU data were analyzed using ANOVA. In RoI where no
significant genotype interactions (with sex or treatment)
were detected, the main effect of genotype was accepted,
using data from all experimental groups. For ketamine and
d-amphetamine-induced effects, data were analyzed in two
separate ANOVAs with sex, genotype, and treatment (saline,
drug) as independent variables. Where significant interactions
were found data were analyzed using post hoc pairwise t-test
with Benjamini–Hochberg correction.
Functional Brain Network Analysis
Global Network Properties and Regional Importance: Graph Theory
Analysis
Global brain network properties and regional centrality were
analyzed using data from saline-treated animals to avoid the
confounding effect of drug treatment (Dawson et al. 2013, 2014a;
Schwarz et al. 2007). The application of brain network analysis
to 14C-2-DG imaging data has previously been described in detail
(Dawson et al. 2012, 2013, 2014b). The algorithms applied allow
us to define global brain network properties and the importance
of each RoI in the network (regional centrality).
Inter-regional Correlations and Functional Brain
Networks
The inter-regional Pearson’s correlation coefficient was used
as the metric of functional association between brain regions,
generated from the 14C-2-DG uptake ratios for each RoI across all
animals in the same experimental group (i.e.,WT or Nrxn1α+/−).
These correlations were Fisher z-transformed to give the data a
more normal distribution. This resulted in the generation of a
pair of {59 × 59} correlation matrices, each within-group matrix
representing the specific association strength between each of
the possible 1711 possible pairs of regions. From each correlation
matrix (R), a binary adjacency matrix (A), where the functional
connection between two regions (ai,j element) was zero if the
Pearson’s correlation coefficient was lower than the defined
threshold (p|i,j| <T) and unity if it was greater to or equal to the
threshold (p|i,j| ≥T), was generated. The adjacency matrix was
then used for graph theory (network) analysis. The adjacency
matrix can also be represented as an undirected graph G, where
a line or edge represents the functional interaction between two
RoI (also known as nodes) if the correlation coefficient exceeds
the defined threshold value.
Network Analysis
Network analysis was completed using the igraph package
(Csardi and Nepsuz 2006) in R (R Core Team 2018). Network
architecture was characterized at the global and regional
scale, with global network architecture quantified in terms of
the mean degree (<k>), average path length (Lp), and mean
clustering coefficient (Cp) of the whole brain network. Regional
properties were defined in terms of degree (ki), betweenness (Bc),
and eigenvector (Ec) centrality. Global and regional metrics were
determined on the binary adjacency matrices generated over a
range of correlation thresholds (Pearson’s r, T=0.49–0.59) that
were selected on the basis that the maximum threshold yielded
fully connected networks in each experimental group.
Global Network Architecture
The degree of a network node (k), in this case a brain RoI,
is simply the number of edges that connect the node to the
network, with highly connected nodes having a high degree.
The mean degree (<k>) is the average number of edges across
all nodes in the network. A sparse network therefore has a low
mean degree.
The minimum path length between two nodes in a graph
(Li,j) is the smallest number of edges that must be traversed to
make a connection between them. If two nodes are immediate
neighbors, directly connected by a single edge, then Li,j = 1. The
average path length (Lp), or the average Li,j across all possible
node pairs, is the average number of steps along the shortest
paths across the network. This provides ameasure of global net-
work efficiency, where networks with low average path length
are more efficient for information transfer.
The clustering coefficient of a node i (Ci) is the ratio of the
number of edges that exist between neighbors of that node rel-
ative to the maximum number of possible connections between
them. This gives an indication of howwell connected the neigh-
borhood of a node is. The mean clustering coefficient (Cp) is the
average clustering of all nodes in the network, which provides a
measure of local density, or the cliquishness, of the network. A
high Cp suggests high clustering and so efficient local informa-
tion transfer.
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The significance of genotype-induced alterations in global
network properties was determined by comparison of the real
difference in each measure to that generated from 55000 ran-
dom permutations of the data (5000 permutations at each cor-
relation threshold). Significance was set at P<0.05.
Regional Centrality
In this study, we considered node centrality in terms of degree
(ki), betweenness (Bc), and eigenvector (Ec) centrality. Degree
centrality (ki) simplymeasures the number of nodal connections
(edges) a node has. Betweenness centrality (Bc) is based on
how many short paths go through a given node, with nodes
having high betweenness centrality thus being more important
in the network. Eigenvector centrality (Ec) indicates the relative
importance in the network of the nodes that the node of inter-
est is connected to (i.e., the importance of a nodes connected
neighbors) and thus gives an indication of a nodes influence in
the network.
A brain region is considered to be an important network hub
when it has a high ki, Bc or Ec. In this study, a RoI was defined
as a hub in the brain network of the given experimental group if
the regional centrality in the real network relative to that of cali-
brated Erdös–Rényi graphs (1000 graphs at each threshold, 11 000
in total) was z>1.96 (Supplementary Material, Supplementary
Table 2). The significance of genotype-induced alterations in
regional centrality was determined by comparison of the z-
score difference in the real networks to that in 55 000 random
permutations of the real data (5000 per correlation threshold).
Significance was set at P<0.05.
Regional Functional Connectivity: Partial Least Squares
Regression
Following identification of Nrxn1α+/−-induced alterations in
regional centrality (Table 1), we employed partial least squares
regression (PLSR) analysis to determine the alterations in
inter-regional connectivity underlying these observations. The
application of PLSR to 14C-2DG imaging data has previously
been outlined in detail (Dawson et al. 2013; Mouro et al.
2018) and was undertaken using the PLS package (Mevik and
Wehrens 2007) in R. Significant regional connectivity to the
“seed” RoI was considered to exist if the lower bound of the
95% confidence interval (CI) of the variable importance to the
projection (VIP) statistic (estimated by jack-knifing) exceeded
the 1.0 threshold. Altered connectivity in Nrxn1a+/− mice was
determined by comparison of the VIP statistic to that in WT
mice (t-test with Bonferroni correction). Lost connectivity
was confirmed by a 95% VIP CI lower bound >1.0 in WT
and<1.0 in Nrxn1a+/− mice, while gained connectivity was
confirmed by a 95% VIP CI lower bound <1.0 in WT and >1.0 in
Nrxn1a+/− mice.
As ketamine corrected thalamic metabolism in Nrxn1a+/−
mice (Fig. 3), we employed PLSR analysis to characterize the
impact of ketamine on the connectivity of these regions in
Nrxn1a+/− mice. As these regions showed lost connectivity in
saline-treated Nrxn1a+/− mice (Table 1, Fig. 2), we determined
regional connectivity that was increased by ketamine admin-
istration in Nrxn1a+/− mice (t-test with Bonferroni correction
and VIP 95% CI lower bound >1.0) and not significantly different
to that seen in saline-treated WT mice (t-test with Bonferroni
correction).
Table 1 Regional centrality alterations in functional brain networks
of Nrxn1α+/− mice
Brain region of interest
(RoI)
Eigenvector
(Ec)
Betweenness
(Bc)
Degree
(<ki>)
Prefrontal cortex
Anterior prelimbic cortex
(aPrL)
−4.27∗ −1.97 −3.97∗
Septum/DB
Medial septum (MS) 3.92∗ 0.60 2.07
Lateral septum (LS) 3.31∗ 1.91 1.44
Vertical limb DB (VDB) 4.08∗ 0.82 2.83
Horizontal limb DB (HDB) 3.81∗ −2.52 1.02
Thalamus
Mediodorsal (MD) −3.67∗ −0.83 −1.76
Centromedial (CM) −4.04∗ −0.06 −3.27
Reuniens (Re) −3.69∗ 0.79 −0.69
Dorsal reticular (dRT) −3.86∗ −0.69 −2.70
Ventral reticular (vRT) −3.57∗ −0.96 −1.23
Basal ganglia
Substantia nigra pars
reticulata (SNR)
−0.30 6.00∗ 2.41
Amygdala
Central amygdala (CeA) 2.89∗ 2.33 2.09
Dorsal hippocampus
Cornu Ammonis 2 (CA2) 3.37∗ 1.04 2.38
Mesolimbic system
Nucleus accumbens
shell (NacS)
2.97∗ 1.91 1.84
Serotonergic system
Median raphé (MR) 0.28 6.85∗ −0.84
Data shown as regional standardized z-score difference between
Nrxn1alpha+/− and WT mice. Bold denotes a significant hub (+ve) or
exteriority (−ve) region in the network of Nrxn1alpha+/− mice that does
not have that status in WT controls. p<0.05 significant difference between
Nrxn1alpha+/− and WT mice (55,000 data permutations).
Results
Nrxn1α+/− Mice Show Thalamic, Mesolimbic, and
Striatal Hypermetabolism with a Contrasting Cortical
and Amygdala Hypometabolism
Nrxn1α+/− mice showed hypermetabolism in multiple thalamic
nuclei, including the ventral reticular thalamus (vRT, P=0.030),
nucleus reuniens (Re, P=0.007), and the ventrolateral (VL,
P=0.023) and ventromedial (VM, P=0.005) thalamic nuclei
(Fig. 1). Nrxn1α+/− mice also showed hypermetabolism in
the ventral tegmental area (VTA, F[1,54] =4.21, P=0.045) and
ventromedial striatum (VMST, F[1,54] =4.59, P=0.036).
By contrast, Nrxn1α+/− mice showed hypometabolism in
select cortical regions, including primary sensory processing
cortices (somatosensory (SSCTX, F[1,54] =5.20, P=0.016) and
auditory (AudC, F[1,54] =5.59, P=0.022) cortex) and in the
entorhinal cortex (EC, F[1,53] =4.50, P=0.039), the cortical
interface between the hippocampus and neocortex (Witter et
al. 2017). In addition, Nrxn1α+/− mice showed hypometabolism
in the central amygdala (CeA, F[1,54] =5.29, P=0.025).
There was no evidence, in any RoI, that sex significantly
influenced the impact of Nrxn1α heterozygosity on cerebral
metabolism. Full data are shown in Supplementary Material,
Supplementary Table 1.
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Figure 1. Constitutive cerebral metabolism is altered in the thalamus, mesolimbic system, cortex, and amygdala in Nrxn1α+/− mice. Nrxn1α+/− mice show
hypermetabolism in the (A–C) thalamus and (D) ventral tegmental area with a contrasting hypometabolism in (E, F) primary sensory processing cortices, (G) entorhinal
cortex, and (H) central amygdala. Data shown asmean±SEM.+P<0.05main effect of genotype, ANOVA. ∗P<0.05, pairwise t-test with Benjamini–Hochberg correction.
VL, VM, and Re data from saline-treated animals only. VTA, SSCTX, AudC, EC, and CeA data are for the genotype effect across all treatment groups.
Average Path length (Lp) Is Increased in Functional
Brain Networks of Nrxn1α+/− Mice
In terms of global brain network properties, we found that the
average path length (Lp) was significantly increased (P=0.041)
in functional brain networks of Nrxn1α+/− mice (Fig. 2), sug-
gesting that the ability of information to transmit across brain
networks is significantly reduced in Nrxn1α+/− mice. We found
no evidence that the number of connections (meandegree (<k>),
P=0.589) or clustering (clustering coefficient (Cp), P=0.277) was
altered in functional brain networks of Nrxn1α+/− mice.
Brain Region Importance Is Altered in Functional Brain
Networks of Nrxn1α+/− Mice
Through centrality analysis,we identified significant alterations
in regional importance in the functional brain networks of
Nrxn1α+/− mice (Table 1). Multiple thalamic regions, including
the mediodorsal (MD), centromedial (CM), Re, dorsal reticu-
lar thalamus (dRT), and vRT, showed reduced centrality in
Nrxn1α+/− mice (Ec). The anterior prelimbic cortex (aPrL) also
showed reduced centrality in Nrxn1α+/− mice (<ki>and Ec).
By contrast, all nuclei of the septum/diagonal band (DB) of
Broca system (lateral septum (LS), medial septum (MS), vertical
(VDB) and horizontal (HDB) limbs of the diagonal band of Broca)
showed increased centrality inNrxn1α+/− mice (Ec). The Ec of the
central amygdala (CeA), CA2 subfield of the dorsal hippocam-
pus (DHCA2), the globus pallidus (GP), and nucleus accumbens
shell (NacS) was also significantly increased in Nrxn1α+/− mice,
while the substantia nigra pars reticulata (SNR) and serotonergic
median raphé (MR) also showed increased Bc in brain networks
of Nrxn1α+/− mice (Table 1). Full data are shown in Supplemen-
tary Table 2.
Compromised Thalamic “Rich-Club,” Thalamic-PFC
and Abnormal Septum/DB, Mesolimbic and Raphé-PFC
Connectivity in Nrxn1α+/− Mice
Rich club architecture in brain networks indicates that highly
connected regions (hubs) are also highly connected to each
other. In saline-treated WT mice, centrality analysis identified
multiple thalamic regions (MD, dRT, VL) as significant hubs
(SupplementaryMaterial, Supplementary Table 2). PLSR analysis
in these animals identified functional connectivity between
thalamic hubs in these animals (Supplementary Tables 4–8),
supporting the rich club status of these thalamic nuclei, as
previously reported in rats (Dawson et al. 2012) and humans (van
den Heuvel and Sporns 2011). The rich club nature of thalamic
nuclei in saline-treatedWTmicewas further confirmed through
the application of algorithms specifically assessing rich club
structure (Ma and Mondragon 2015). Using these algorithms,
multiple thalamic nuclei (dRT, vRT, Re, CM, CL) and PFC subfields
(aPrL,Cg1)were identified asmembers of the rich club core (RCC)
in functional brain networks of saline-treated WT mice. These
regions were not part of the RCC in saline-treated Nrxn1a+/−
mice (supplemental material, RCC analysis). PLSR analysis con-
firmed lost interconnectivity between these thalamic nuclei
in Nrxn1α+/− mice (Fig. 2), supporting compromised thalamic
“rich club” connectivity in these animals. We also found sig-
nificant evidence for lost PFC-thalamus functional connectivity
in Nrxn1α+/− mice (Fig. 2). These reductions in inter-regional
and “rich club” connectivity would contribute to the increased
network average path length (Fig. 2) seen in Nrxn1α+/− mice.
PLSR analysis also identified abnormal inter-regional con-
nectivity in Nrxn1α+/− mice that is not present in WT animals,
contributing to the increased centrality of selected brain regions
in theNrxn1α+/− mice (Table 1). This included abnormal connec-
tivity between the septum/DB and the PFC, thalamus, mesolim-
bic and auditory systems inNrxn1α+/− mice thatwas not present
in WT controls. In addition, Nrxn1α+/− mice had connectivity
between the medial raphé (MR) and PFC that was not present
in WT controls (Fig. 2). Full data are shown in Supplementary
Tables 3–18.
Subanesthetic Ketamine Administration Normalizes
Thalamic Hyperactivity in Nrxn1α+/− Mice
In linewith previous reports, ketamine administration increased
LCGU in the PFC, hippocampus and striatum while reducing
LCGU in thalamic nuclei (Dawson et al. 2013, 2015). Sub-
anesthetic ketamine administration effectively reversed the
constitutive thalamic hypermetabolism seen in Nrxn1α+/− mice,
bringing metabolism to a similar level to that seen in WT
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Figure 2. Nrxn1α heterozygosity alters functional brain network structure and inter-regional functional connectivity. (A) Average path length is significantly increased
(Lp, P=0.041) in functional
AQ9
brain networks of Nrxn1α+/− mice, while (B) mean degree (<k>, P=0.589) and (C) the global clustering coefficient (Cp, P=0.277) are not
altered. Inter-regional functional connectivity alterations in Nrxn1α+/− mice support reduced thalamic “rich club,” thalamic-PFC and abnormal septum/DB and raphé-
PFC connectivity. (D) Heatmap showing significantly lost (blue) and abnormal/gained (red) inter-regional connectivity in Nrxn1α+/− relative to WT mice, determined
by comparison of the VIP statistic (t-test with Bonferroni correction) calculated through PLSR analysis. (E) Brain images showing the anatomical localization of altered
inter-regional connectivity for the anterior prelimbic cortex (aPrL), dorsal reticular thalamus (dRT), and nucleus reuniens (Re) “seed” regions (yellow). Blue denotes
functional connectivity present inWTmice (VIP 95%CI>1.0) that is significantly lost inNrxn1α+/− mice (VIP 95%CI<1.0, and P< 0.05 t-test with Bonferroni correction).
5-HT, serotonergic system; Amg, amygdala; Aud, auditory system; BG, basal ganglia; Hipp, hippocampus; Meso, mesolimbic system; PFC, prefrontal cortex; Sept/DB:
septum/diagonal band of Broca. Brain images adapted from the Allen mouse brain atlas (mouse.brain-map.org/static/atlas).
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Figure 3. Subanesthetic ketamine administration normalizes thalamic metabolism and restores thalamic hub and reticular thalamus–nucleus reuniens–prefrontal
cortex (RT–Re–PFC) circuit connectivity in Nrxn1α+/− mice. (A–D) Subanesthetic ketamine administration normalizes thalamic hyperactivity in Nrxn1α+/− mice. (E)
Nrxn1α+/− mice show an enhanced cerebral metabolic response to ketamine in the nucleus accumbens core (NacC). (F, G) The impact of ketamine on PFC and
hippocampal function is not altered inNrxn1α+/− mice. Data shown asmean±SEM.Nrxn1α Hz=Nrxn1α+/− mice. ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.001 ketamine effect
within genotype and ++P<0.01, +++P<0.001 genotype effect within treatment group (t-test with BH correction). ##P<0.01, ###P< 0.001 ketamine effect (ANOVA) in
regions where no significant genotype × treatment interaction found. (H) Summary connectivity map showing the functional connections of thalamic hub regions lost
in Nrxn1α+/− mice that are restored by ketamine administration. Black shading denotes lost connectivity in saline-treated Nrxn1α+/− mice that is restored to the level
seen in wild-type mice in ketamine-treated Nrxn1α+/− mice. (I) Summary diagram of RT–Re–PFC circuit connectivity restored in Nrxn1α+/− mice by subanesthetic
ketamine administration. aPrL, anterior prelimbic cortex; CM, centromedial thalamus; dRT, dorsal reticular thalamus; MD,mediodorsal thalamus; Re, nucleus reuniens;
VHCA2, ventral hippocampus CA2; VO, ventral orbital cortex; vRT, ventral reticular thalamus; SNC, substantia nigra pars compacta. Representative autoradiograms are
shown in Supplementary Fig. 1.
controls and WT mice treated with ketamine (Fig. 3). Saline-
treated Nrxn1α+/− mice displayed thalamic hyperactivity as
compared to saline-treated WT animals in the VM (P=0.005),
Re (P=0.007), vRT (P=0.030), and dRT (trend, P=0.062). While
ketamine reduced LCGU in these regions in Nrxn1α+/− mice
(VM, P=0.002; Re, P<0.001; dRT, P<0.001; vRT, P<0.001), it was
not significantly altered in WT mice (VM, P=0.961; Re, P=0.650;
dRT, P=0.388), with the exception of the vRT (P=0.018) where
ketamine also reduced LCGU inWTmice. LCGU in these regions
was not significantly different in ketamine-treated Nrxn1α+/−
mice as compared to saline-treated WT mice (VM, P=0.961; Re,
P=0.486; dRT, P=0.123) with the exception of the vRT, which
was significantly different from that in saline (P=0.007) but
not ketamine-treated (P=0.800) WT mice. These effects were
supported by a significant genotype × treatment interaction
in each region (VM, F[1,32] = 6.472, P=0.016; Re, F[1,32] = 6.703,
P=0.014; dRT, F[1,32] = 5.057, P=0.035; vRT, F[1,32] = 4.246, P=0.048).
In addition to these changes, ketamine increased LCGU in the
nucleus accumbens core (NacC) of Nrxn1α+/− mice (P<0.001)
but not in WT animals (P=0.234), with NacC metabolism
in ketamine-treated Nrxn1α+/− mice being higher than that
in saline-treated WT animals (P=0.025). The altered NacC
metabolic response to ketamine in Nrxn1α+/− mice was
supported by a significant genotype × treatment interaction
(F[1,32] = 4.527, P=0.041).
In contrast to these modified responses, the impact of
ketamine on LCGU in all PFC and hippocampal RoI was not
altered in Nrxn1α+/− mice (Fig. 3). Full data are available in
Supplementary Table 1.
Subanesthetic Ketamine Administration Restores
Thalamic “Rich Club” Hub and Reticular
Thalamus–Nucleus Reuniens–Prefrontal (RT–Re–PFC)
Functional Connectivity in Nrxn1α+/− Mice
To elucidate the impact of ketamine administration on thalamic
connectivity in Nrxn1α+/− mice, we employed PLSR analysis to
characterize the inter-regional functional connectivity of tha-
lamic “rich club” regions showing decreased connectivity in
saline-treated Nrxn1α+/− mice (Table 1, Fig. 2; Re, dRT, vRT, MD,
CM). Given the ability of ketamine administration to normalize
LCGU in thalamic regions in Nrxn1α+/− mice (Fig. 3), we deter-
mined the lost connectivity present in saline-treated Nrxn1α+/−
mice restored by ketamine administration.
In Nrxn1α+/− mice, ketamine restored inter-regional func-
tional connectivity between thalamic “rich club” brain regions
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and between the Re-PFC, effectively restoring connectivity in the
reticular thalamus–nucleus reuniens–prefrontal cortex circuit
(RT-Re-PFC, Fig. 3). In Nrxn1α+/− mice, ketamine also increased
dRT-Re functional connectivity, bringing it to a similar level to
that seen in WT control mice, re-establishing functional con-
nectivity between these regions. Similarly, for the Re, ketamine
increased connectivity to the CM thalamic nucleus and two PFC
subfields (aPrL, VO) in Nrxn1α+/− mice, restoring it to a similar
level to that seen inWTcontrols. For the vRT,ketamine increased
functional connectivity to the CM and SNC in Nrxn1α+/− mice,
restoring connectivity to a level similar to that seen in WT
controls. When the CM was considered as the seed region in
PLSR analysis, the restoration of functional connectivity to the
Re and vRTwas confirmed. Finally,when theMDwas considered
as the seed region, ketamine increased connectivity to the AM
thalamic nucleus and CA2 subfield of the ventral hippocampus
(VHCA2), restoring connectivity to a similar level seen in WT
controls. Full PLSR connectivity data are shown in Supplemen-
tary Tables 3–18 and Supplementary Fig. 2.
Overall, these data suggest that subanesthetic ketamine
administration effectively restores functional connectivity
between thalamic “rich club” regions in Nrxn1α+/− mice and
re-establishes thalamic-PFC functional connectivity (Re, Fig. 3).
This suggestion is further supported by the observation that
these thalamic nuclei (dRT, vRT, Re, MD, CM) form part of the
RCC in ketamine-treated, but not saline-treated,Nrxn1α+/− mice
(Supplemental Material, RCC analysis).
The Cerebral Metabolic Response to
Dextro-Amphetamine Is Not Altered in Nrxn1α+/− Mice
In keeping with previous observations, d-amphetamine admin-
istration induced hypometabolism in the PFC, amygdala, and
ventral hippocampus along with hypermetabolism in the tha-
lamus, substantia nigra (pars compacta, SNC), and retrosplenial
(RSC) cortex (Ernst et al. 1997; Miyamoto et al. 2000).We found no
evidence, in any RoI, that the LCGU response to d-amphetamine
was significantly altered in Nrxn1α+/− mice (Fig. 4). Full data are
shown in Supplementary Table 1.
Discussion
We have, for the first time, identified the alterations in constitu-
tive cerebralmetabolism and functional brain network structure
that result fromheterozygousNrxn1α deletion.These alterations
have translational relevance to neurodevelopmental disorders
for which NRXN1 deletions are a genetic risk factor, including
ASD and ScZ, and to individuals with 2p16.3 (NRXN1) dele-
tions. The data show that ketamine administration can restore
the thalamic metabolism and dysconnectivity, including the
compromised thalamic “rich club” and RT–Re–PFC connectivity,
which result from heterozygous Nrxn1α deletion. This suggests
that altered NMDA-R activity may underlie the thalamic dys-
function seen in Nrxn1α+/− mice, although this requires further
investigation. Overall, the data suggest that ketamine adminis-
tration and NMDA-R antagonismmay be an effective strategy to
restore the thalamic-PFC dysfunction that results from 2p16.3
(NRXN1) deletion. This may also have translational relevance to
the reported therapeutic benefit of NMDA-R antagonists in ASD,
although further characterization in Nrxn1α+/− mice would be
needed to establish this more firmly.
Translational Relevance of the Brain Network
Connectivity Deficits Present in Nrxn1α+/− Mice
The alterations in cerebral metabolism and brain network con-
nectivity seen in Nrxn1α+/− mice may contribute to the reported
behavioral alterations seen in these animals and have transla-
tional relevance to the functional brain imaging deficits seen in
ASD and ScZ.
Behavioral deficits previously reported in Nrxn1α+/− mice
include hyperactivity, altered habituation, deficits in object
recognition and social memory, and deficits in associative
learning (as measured by passive avoidance) (Laarakker et
al. 2012; Dachtler et al. 2015). While behavioral deficits in
Nrxn1α+/− mice are not always found (Grayton et al. 2013), the
published data generally support deficits in associative learning
and recognition learning and memory as a consequence of
Nrxn1α heterozygosity. In rodents, the neural circuitry for object
recognition memory includes the PFC, hippocampus, thalamus,
perirhinal cortex, and entorhinal cortex (Antunes and Biala 2012;
Warburton and Brown 2015),while the neural circuitry for rodent
social recognition includes the PFC, hippocampus, septum, and
amygdala (Bicks et al. 2015). Intriguingly, we found evidence
for regional metabolic dysfunction and altered connectivity
in Nrxn1α+/− mice within these neural systems, which could
contribute to the behavioral deficits seen in these animals.
This includes entorhinal cortex (EC) and central amygdala
(CeA) nucleus hypofunction along with altered thalamic-PFC
and septum-PFC connectivity (Fig. 2). In addition, we also found
evidence for compromised nucleus reuniens (Re) connectivity
to both the PFC and hippocampus in Nrxn1α+/− mice. While a
direct glutamatergic projection exists from the hippocampus to
the PFC, information from the PFC to the hippocampus is relayed
through the nucleus reuniens (Vertes 2002). Thus, compromised
connectivity in the PFC–Re–hippocampal circuit in Nrxn1α+/−
mice could contribute to the deficits in learning and memory
seen in these animals. Interestingly, deficits in the functional
connectivity of this neural circuit have been reported in another
mouse model of genetic risk for ASD and ScZ (Disc1, Dawson
et al. 2015), suggesting that this may be a common neural
pathway affected by genetic mutations associated with ASD and
ScZ.
We also found evidence for increased activity in motor tha-
lamic nuclei (VL and VM) in Nrxn1α+/− mice, and our ketamine
data suggest that NMDA-R dysfunction may contribute to the
increased neuronal activity of these motor thalamic regions
(Fig. 3). The VL and VM, along with other motor areas, including
the cerebellum, basal ganglia, and motor cortex, play a key role
in motor learning in rodents (Ding et al. 2002; Jeljeli et al. 2003).
Intriguingly, we found evidence for enhanced motor learning
abilities in Nrxn1α+/− mice in the accelerating rotarod test (Sup-
plementary Material, Supplementary Fig. 3), which mirrors that
previously reported in Nrxn1α knockout mice (Etherton et al.
2009). This suggests that enhanced neuronal activity andNMDA-
R function in motor circuitry may contribute to the enhanced
motor learning abilities of Nrxn1α+/− mice.
The alterations in brain function and network connectivity
seen in Nrxn1α+/− mice may also have translational relevance
to the functional brain imaging deficits seen in ASD and ScZ.
For example, thalamic dysfunction is widely supported in
both ASD and ScZ with thalamic hypofunction rather than
hyperfunction, as seen in Nrxn1α+/− mice, generally reported
(Buchsbaum et al. 1996; Hazlett et al. 2004; Haznedar et al. 2006).
However, in humanbrain imaging studies, the small and discrete
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Figure 4. Cerebral metabolic responses to d-amphetamine are not altered in Nrxn1α+/− mice. Data shown as mean±SEM of the 14C-2-DG uptake ratio.
d-Amphetamine (d-Amph) administration induces (A) medial orbital cortex hypometabolism, (B–E) thalamic hypermetabolism, and (F, G) amygdala and (H, I)
hippocampal hypometabolism. We found no evidence, in any brain region where d-amphetamine modified cerebral metabolism, that the response was altered in
Nrxn1α+/− mice. Data shown as mean±SEM. #P<0.05, ##P<0.01 and ###P<0.001 significant effect of d-amphetamine (ANOVA).
thalamic nuclei identified as hyperactive in Nrxn1α+/− mice,
including the RT and Re, have not previously been resolved.
Moreover, recent studies with greater anatomical resolution
have identified complex patterns of thalamic dysfunction,
including both regional hypoactivation and hyperactivation, in
these disorders, dependent on the thalamic nuclei characterized
and the cognitive state of patients during testing (Pergola et
al. 2015; Mitelman et al. 2018). Interestingly, while studies of
brain function in ASD rodent models are limited, the thalamic
hyperfunction seen in Nrxn1α+/− mice parallels that recently
reported in another rodent model relevant to the disorder
(Cho et al. 2017). Other alterations in cerebral metabolism
present inNrxn1α+/− mice with translational alignment to those
reported in ASD and ScZ include amygdala (CeA) and entorhinal
cortex (EC, brodmans 28/34) hypofunction, which parallels the
temporal lobe hypofunction and the direct hypofunction of
these structures in these disorders (Carina Gilberg et al. 1993;
Zakzanis et al. 2000; Aoki et al. 2015; Mitelman et al. 2018).
The data suggest that the RT is a primary locus of tha-
lamic dysfunction as a consequence of Nrxn1α heterozygos-
ity, evidenced by altered RT metabolism and connectivity in
Nrxn1α+/− mice. While direct evidence from functional brain
imaging studies to support RT dysfunction in ASD and ScZ is
currently lacking, a range of evidence supports RT dysfunction
in these disorders. For example, the RT plays a key role in
processes dysfunctional in both ASD and ScZ, including sleep,
the generation of brain oscillations, sensory integration, and
cognition (Pratt and Morris 2015; Krol et al. 2018). Recent cellular
evidence directly supports RT dysfunction in ScZ (Steullet et
al. 2018), while direct evidence for RT dysfunction in ASD is
currently lacking. However, a primary cell type in the RT are
parvalbumin positive (PV+) interneurons (Tanahira et al. 2009),
and PV+ expression is altered in both ASD (Lawrence et al. 2010;
Hashemi et al. 2017) and ScZ (Beasley and Reynolds 1997; Zhang
and Reynolds 2002). While these studies have characterized
PV+ cells in the PFC and hippocampus, recent studies have
also confirmed RT PV+ cell dysfunction in ScZ (Steullet et al.
2018). This remains to be characterized in ASD. However, the
RT and PV+ neurons are known to be dysfunctional in other
preclinical rodent models relevant to ASD and ScZ, including
models involving NMDA-R dysfunction (Cochran et al. 2003;
Dawson et al. 2012, 2015; Wells et al. 2016). Moreover, as NMDA-
R hypofunction is able to induce both RT PV+ cell dysfunction
and RT hypometabolism (Cochran et al. 2003; Dawson et al. 2012,
2013), andNMDA-Rs directly regulate the activity of PV+neurons
(Carlen et al. 2012; Miller et al. 2016), PV+ neuron dysfunction
may contribute to the NMDA-R dependent thalamic dysfunction
seen in Nrxn1α+/− mice. This suggestion is further supported
by the observation that parvalbumin directly regulates neuronal
activity in the RT (Alberi et al. 2012). As other thalamic (VPM,
VPL) and cortical (SSCTX) regions found to be dysfunctional in
Nrxn1α+/− mice also contain high levels of PV+ cells (Tanahira
et al. 2009), dysfunction of this cell type may also contribute
to the altered metabolism seen in these brain regions. Thus,
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given the potential translational relevance of PV+ cell deficits in
Nrxn1α+/− mice, the possible contribution of PV+ cell dysfunc-
tion to the RT and other brain imaging deficits seen inNrxn1α+/−
mice certainly warrants further systematic investigation.
While Nrxn1a heterozygosity did not reproduce the overt
PFC hypometabolism (hypofrontality) reported in ASD and ScZ
(Ohnishi et al. 2000; Hill et al. 2004; Mitelman et al. 2018), PFC
functional connectivity was compromised in Nrxn1α+/− mice.
This mirrors the reduced PFC connectivity reported in ASD and
ScZ and in other relevant genetic mouse models relevant to
these disorders (Sigurdsson et al. 2010; Bertero et al. 2018; Liska
et al. 2018). In Nrxn1α+/− mice, this includes reduced thalamic-
PFC connectivity, mirroring the reduced functional and struc-
tural thalamic-PFC connectivity reported in ASD and ScZ (Nair
et al. 2013; Woodward and Heckers 2016; Giraldo-Chica and
Woodward 2017; Woodward et al. 2017). The reduced intercon-
nectivity of thalamic nuclei in Nrxn1α+/− mice, contributing to
the loss of thalamic “rich club”hubs, also parallels the decreased
interconnectivity between thalamic nuclei in ASD (Tomasi and
Volkow 2019) and ScZ (Tomasi and Volkow 2014) and mirrors
the loss of brain network hubs in these disorders (Rubinov and
Bullmore 2013; Itahashi et al. 2014). We also found broader
evidence for alterations in functional brain network structure
in Nrxn1α+/− mice that mirror those seen in ASD and ScZ. This
includes an increase in the average path length of functional
(Micheloyannis et al. 2006; Barttfeld et al. 2012; Boersma et al.
2013; Itahashi et al. 2014) and structural brain networks (Roine et
al. 2015; Yeo et al. 2016) in these disorders, supporting decreased
efficiency of information transfer across brain networks as a
consequence of Nrxn1α heterozygosity and in these disorders.
Moreover, the hypoconnectivity of functional brain networks
in Nrxn1α+/− mice parallels that reported in other preclinical
models relevant to ASD (Bertero et al. 2018; Liska et al. 2018) and
ScZ (Dawson et al. 2014b).
Nrxn1α Heterozygosity Alters In vivo Glutamate but
Not General Monoaminergic Neurotransmitter System
Function
Our data suggest that Nrxn1α heterozygosity induces NMDA-
R dysfunction that contributes to disturbed neuronal activity
in selected neural circuits, including the mesolimbic system,
posterior thalamic nuclei (VMandVL), and the RT–Re–PFC circuit
(Fig. 3). Intriguingly, our data show that administration of a
subanesthetic dose of the NMDA-R antagonist ketamine cor-
rects the thalamic hypermetabolism and RT–Re–PFC dysfunc-
tion present in Nrxn1α+/− mice. The regulation of glutamatergic
and NMDA-R function by Nrxn1α is supported by a diverse
range of studies (Chubykin et al. 2007; Barrow et al. 2009; de
Wit et al. 2009; Etherton et al. 2009; Espinoza et al. 2015; Dai
et al. 2019). The role of NMDA-R dysfunction in ASD is com-
plex, with both NMDA-R agonists and antagonists reported as
improving ASD symptoms (Lee et al. 2015). NMDA-R antagonists,
such as Memantine and Amantadine, have been shown to have
positive therapeutic effects in ASD (Chez et al. 2007; Ghaleiha
et al. 2013; Nikvarz et al. 2017). Our data suggest that these
effects may be mediated through the correction of abnormal
thalamic and mesolimbic function and the restoration of the
RT-Re-PFC circuit and that thalamic hyperactivity in individu-
als with ASD may offer a biomarker for NMDA-R antagonist
efficacy in the disorder. This conjecture certainly warrants fur-
ther systematic investigation. While our data suggest that the
correction of thalamic hypermetabolism in Nrxn1α+/− mice by
ketamine administration may have translational relevance to
the therapeutic impact of NMDA-R antagonists in ASD, these
effects would need to be confirmed in relation to the behavioral
alterations seen inNrxn1α+/− mice (Laaraker et al. 2012; Dachtler
et al. 2015). Two concerns with regard to behavioral testing
using the dose of ketamine applied in our imaging study are
its ability to induce locomotor hyperactivity (Irifune et al. 1991),
which is likely to impact on performance in many behavioral
tests, and its ability to disrupt PFC and hippocampal func-
tion in Nrxn1α+/− mice (Supplementary Table 1), which is likely
to disrupt behaviors dependent upon these neural systems,
including several of the behaviors reported to be altered in
Nrxn1α+/− mice (Laaraker et al. 2012; Dachtler et al. 2015). Thus,
future studies should be dedicated to testing the efficacy of
lower doses of ketamine, in relation to both the behavioral and
brain imaging alterations seen in Nrxn1α+/− mice, identifying
doses that do not significantly disrupt locomotor activity but
may act to restore behaviors and thalamic function in these
animals.
Another limitation to our study is the mixed pharma-
cology of ketamine, which not only acts as an NMDA-R
antagonist but also displays biological activity at other targets
including hyperpolarization-activated cyclic nucleotide-gated
channels (HCN), cholinergic receptors, dopamine-2 receptors
(D2R), opioid receptors, and voltage-gated sodium channels
(VGSCs). The actions of ketamine are further complicated by
the complex biological activity of its metabolites in vivo (Zanos
et al. 2018). Thus, the suggestion that the ability of ketamine to
restore thalamic function inNrxn1α+/− mice relies on its activity
at NMDA-Rs is made with caution, and further molecular char-
acterization is needed to more strongly support this contention.
Nevertheless, studies showing that Nrxn1α influences NMDA-
R function further support the plausibility of this mechanism
(Chubykin et al. 2007; Barrow et al. 2009; de Wit et al. 2009;
Etherton et al. 2009; Espinoza et al. 2015; Dai et al. 2019).
We also found that generalmonoaminergic neurotransmitter
system functional responses, as evidenced by the LCGU
response to d-amphetamine, were not altered in Nrxn1α+/−
mice (Fig. 4). This suggests that Nrxn1α heterozygosity does
not reproduce the enhanced response to d-amphetamine
seen in ScZ (Breier et al. 1997; Swerdlow et al. 2018) and that
the impact on general monoaminergic system function is
limited. However, the suggestion that these systems are not
altered in Nrxn1α+/− mice is made with caution. Whether the
function of the individual monoaminergic systems (dopamine,
serotonin, noradrenaline) is altered in Nrxn1α+/− mice remains
to be adequately tested. In fact, our observation of increased
functional connectivity between the serotonergic median
raphé (MR) and PFC in Nrxn1α+/− mice (Fig. 2) suggests that
serotonergic neurotransmitter system function may be altered
in these animals.
Interestingly, stimulants including d-amphetamine are used
to treat ADHD-like symptoms (impaired attention, hyperactivity
and impulsivity) in ASD (Nickels et al. 2008; Cortese et al. 2012).
However, we found no evidence that d-amphetamine normal-
ized any of the dysfunctional cerebral metabolism present in
Nrxn1α+/− mice. While hyperactivity is reported in Nrxn1α+/−
mice (Laarakker et al. 2012), impaired attention or impulsivity
is yet to be adequately tested. Our data suggest that Nrxn1α+/−
mice may not provide a useful model of stimulant-based treat-
ment of ADHD-like symptoms in ASD. However, given the ability
of ketamine to restore RT–Re–PFC circuit function in Nrxn1α+/−
mice, a key circuit involved in attentional processing (Prasad
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et al. 2013; Kim et al. 2016;Wells et al. 2016),NMDA-R antagonists
may be able to restore attentional deficits, if found to be present
in these animals. Thus, there appears to be a degree of phar-
macological selectivity with regard to the potential predictive
utility of Nrxn1α+/− mice as a model of therapeutic efficacy in
ASD.
Conclusion
In conclusion, we have identified a range of brain imaging
functional and connectivity deficits in Nrxn1α+/− mice that
have translational relevance to those seen in ASD and ScZ.
This includes the hyperactivity and dysconnectivity of multiple
thalamic nuclei that are partially normalized by subanesthetic
ketamine administration. Thus, Nrxn1α+/− mice may provide
a translational model relevant to the therapeutic efficacy of
NMDA-R antagonists in ASD, while their translational utility in
relation to stimulant compounds in ASD appears to be limited.
Supplementary Material
Supplementary material can be found at Cerebral Cortex online.
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